Completed PHASE3 INTERVENTIONAL 8-arm NCT02175771

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Persistent Asthma

Interventions ADVAIR DISKUS FLOVENT HFA FS MDPI Fp MDPI albuterol/salbutamol HFA

Updated 10 times since 2017 Last updated: Nov 6, 2021 Started: Jul 31, 2014 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Persistent Asthma and is currently completed. Teva Branded Pharmaceutical Products R&D, Inc. leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

May 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — May 2020 [monthly]

Completed PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — May 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bangor, United States , Bellevue, United States , Birmingham, United States , Bryn Mawr, United States , Canton, United States , Charleston, United States , Charlotte, United States , Cincinnati, United States , Coeur d'Alene, United States and 78 more locations